- Designed to act against: HIV-1
- Delivery method: Vaginal ring
- Active ingredients: DS003 and dapivirine, both antiretroviral drugs
- Length of action: Three months
- Status: Development currently paused
Why is the DS003-dapivirine ring important?
DS003 is a potent new ARV that has not been used for HIV prevention. Combining ARVs that have different mechanisms of action to attack HIV may help increase the breadth of protection and reduce the chance of acquiring drug-resistant virus. IPM has been exploring vaginal rings that contain DS003 alone and in combination with dapivirine.
How does the DS003-dapivirine ring work?
Prototype rings have been developed to release both DS003 and dapivirine over time. Women would insert the flexible, long-acting ring themselves into the vagina. DS003 is a gp120 binder not currently used for HIV treatment or prevention.
What is its development history?
IPM negotiated a license to DS003 early in its development. IPM completed a formulation and preclinical program that supported a first-in-human clinical evaluation of DS003 formulated as a single-use vaginal tablet. This initial trial of DS003 (IPM 042) collected safety and pharmacokinetics data to help guide the development of a potential three-month combination ring containing DS003 and dapivirine.
What are the next steps for the DS003-dapivirine ring?
Development of the ring is currently paused due to insufficient funding and organizational priorities. IPM will update this page when development resumes.
Who are IPM's partners to develop and test the ring?
- ARV license: Bristol-Myers Squibb, Janssen Sciences Ireland Unlimited Company
- Development: ProMed Pharma